US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive
The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach.
President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal...
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- US FDA moves to fast-track psychedelic drugs after Trump order - Reuters Reuters —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —